RxDoctor Payments Data

Michael McConnell

Psychiatric/Mental Health · Santa Maria, CANPI 1356693683

Payments from drug & device makers

$1,161in general payments, 2019–2025

Across 47 payments — averaging $24.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$466
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$151
  • Johnson & Johnson$140
  • Teva Pharmaceuticals USA, Inc.$133
  • Otsuka America Pharmaceutical, Inc.$127
  • Sunovion Pharmaceuticals Inc.$99
  • plus $46 from 1 others

What the payments were for

  • Food & beverage$1,161100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,161 in reported general payments places this provider in the 70th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$14,222
Medicare patients
43
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate57$187,106
Invega TrinzaPaliperidone Palmitate21$144,824
AristadaAripiprazole Lauroxil21$63,091
Abilify MaintenaAripiprazole15$34,222
Lurasidone Hcl46$21,448
Aripiprazole96$7,094
Clozapine25$2,471
Quetiapine Fumarate65$1,883
Paliperidone ErPaliperidone17$1,500
Prazosin Hcl29$1,162
Trazodone Hcl149$1,153
Divalproex Sodium16$879
Venlafaxine Hcl ErVenlafaxine Hcl33$786
Duloxetine Hcl75$764
Ziprasidone Hcl13$704

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$140$331,93178 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$127$34,22215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Santa Maria

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →